Factor VIII and Antithrombin III in Atherosclerosis Obliterans of the Lower Limbs

  • G. Avellone
  • V. Mandalà
  • S. Novo
  • A. Pinto
  • F. P. Riolo
  • F. Cannioto
  • G. Raneli
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)


In the multifactorial pathogenesis of atherosclerosis (the W.H.O. gives a list of about forty risk factors) recent acquisitions have allowed to determine in part the role carried out by the term “haemocoagulative disorders” (90) showing the possible connections between haematic components of haemocoagulation and vascular wall that up to now have been only hypothesised.


Factor VIII Atherosclerotic Vascular Disease Arterial Smooth Muscle Cell Coagulant Activity Thrombin Formation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    U. Abilgaard, Inhibition of the thrombin-fibrinogen reaction by antithrombin III studied by N-terminal analysis. Scand. J. Clin. Lab. Inv. 20:205 (1967).Google Scholar
  2. 2.
    U. Abilgaard, Inhibition of the thrombin-fibrinogen reaction by alpha 2-macroglobulin, studied by N-terminal analysis. Thromb. Diath. Haemorrh. 21:173 (1968).Google Scholar
  3. 3.
    L.O. Almer, I.M. Nilsson, On fibrinolysis in diabetes mellitus. Acta Med. Scand. 198:101 (1975).PubMedCrossRefGoogle Scholar
  4. 4.
    H.N. Antoniades, C.D. Scher, Growth factor derived from human serum, human platelets and human pituitary: properties and immunological cross reactivity. J. Natl. Cancer Institute p. 137 (1978).Google Scholar
  5. 5.
    G. Avellone, V. Mandalà, G. Raneli, Coagulazione, aggregazione piastrinica, fibrinolisi in pazienti affetti da arteriopatia ad evoluzione obliterante degli arti inferiori. In: Di Matteo G. & Pola P. (eds.): Atti I Congresso Nazionale della Società Italiana di Patologia Vasculare, p. 231, ERRE.DI.E., Roma, 1979.Google Scholar
  6. 6.
    G. Avellone, S. Novo, G. Davì, G. Abruzzese, Plasmatic fibrinogen, plasminogen and antithrombin III levels in atherosclerotic patients. In: Strano A. (ed.): Proceedings of European Symposium on advances in coagulation, fibrinolysis, platelet aggregation and atherosclerosis, p. 183, C.E.P.I., Roma, 1978.Google Scholar
  7. 7.
    G. Avellone, V. Mandalà, F.P. Riolo, A. Pinto, Antithrombin III in patients with atherosclerotic vascular disease. Abstracts of: First International “Colloquy” of Angiology, p. 271, Firenze, 1979.Google Scholar
  8. 8.
    N.U. Bang, M.L. Chang, Soluble Fibrin complexes. Sem. Thromb. Haemostas. 1:91 (1974).Google Scholar
  9. 9.
    D. Bensoussan, S. Levi-Toledano, P. Passa, Platelet hyperaggregation in increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologia 11:307 (1975).PubMedCrossRefGoogle Scholar
  10. 10.
    R. Biggs, K.W.E. Denson, N. Alkman, R. Barrett, M. Hadden, Antithrombin III, antifactor Xa and heparin. Br. J. Haematol. 19:283 (1970).PubMedCrossRefGoogle Scholar
  11. 11.
    R. Biggs, The absorption of human F. VIII neutralising antibody by factor VIII. Br. J. Haematol. 26:259–268 (1974).PubMedCrossRefGoogle Scholar
  12. 12.
    T.K. Bills, J.B. Smith, M.J. Silver, Metabolism of (14C) arachidonic acid by human platelets. Biochim. Biophys. Acta 124: 303 (1976).Google Scholar
  13. 13.
    A.L. Bloom, J.C. Giddings, G.R. Peake, Low molecular weight factor VIII. Lancet 1:661–662 (1973).PubMedCrossRefGoogle Scholar
  14. 14.
    A.L. Bloom, G.R. Peake, J.C. Giddings, The presence and reactions of high and lower molecular weight procoagulant F.VIII in the plasma of patients with von Willebrand disease after treatment; significance for a structural hypothesis for F.VIII. Thromb. Res. 3:389–404 (1973).CrossRefGoogle Scholar
  15. 15.
    A.L. Bloom, S.C. Giddings, C.J. Wilks, Factor VIII on vascular intima: possible importance in hemostasis and thrombosis. Nature. New Biology 241:217 (1973).PubMedCrossRefGoogle Scholar
  16. 16.
    B. Boneu, M. Abbal, J. Plante, R. Bierme, Factor VIII complex and endothelial damage. Lancet 1:1430 (1975).PubMedCrossRefGoogle Scholar
  17. 17.
    B. Boneu, D. Durand, F. Counillan, J.P. Charlet, R. Bierme, J.M. Sue, Increased level of factor VIII complex in severe arterial hypertension. Haemostasis 7:332 (1978).PubMedGoogle Scholar
  18. 18.
    B.N. Bouma, J.M. Hordijk-Hoss, S. De Graaf, J.J. Sixma, J.A. Van Mourik, Presence of factor VIII related antigen in blood platelets of patients with von Willebrand’s disease. Nature 257:510 (1975).PubMedCrossRefGoogle Scholar
  19. 19.
    C. Busch, J. Dawes, D.S. Pepper, A. Wasteson, Binding of platelet factor 4 to cultured human endothelial cells. Thrombos. Haemostas. 42:43 (1979).Google Scholar
  20. 20.
    C. Cavallero, Modificazioni della parete arteriosa nell’arteriosclerosi. In: Cardiología Oggi, vol. 1, p. 193, Ed. Med. Scient., Torino 1975.Google Scholar
  21. 21.
    A.B. Chandler, Thrombosis and the development of atherosclerosis lesion. In: Jones R. (ed.): Atherosclerosis, p. 88, Springer, New York, 1970.Google Scholar
  22. 22.
    A.B. Chandler, I. Chapman, L.R. Erhardt, W.C. Roberts, J.C. Schwartz, D. Sinapius, D.M. Spain, S. Sherry, P.M. Neiss, T.L. Simon, Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am. J. Cardiol. 34:823 (1974).PubMedCrossRefGoogle Scholar
  23. 23.
    P.S. Damus, M. Hicks, R.D. Rosenberg, A generalized view of heparin’s anticoagulatnt action. Nature 246:355 (1973).PubMedCrossRefGoogle Scholar
  24. 24.
    M.J. Davies, N. Woolf, J.W.P. Bradley, Endothelialisation of experimentally produced mural thrombi in the pig aorta. J. Pathol. 97:589 (1969).PubMedCrossRefGoogle Scholar
  25. 25.
    K.W.E. Denson, Reagents and techniques, In: The treatment of haemophilia and other clotting disorders. Ed. by R. Biggs and R.G. Macfarlane, p. 337. Blackwell Scientific Publication, Oxford 1966.Google Scholar
  26. 26.
    K.W.E. Denson, Standardization of methods for the determination of factor VIII. Thrombos. Diathes. Haemorrh. Suppl. 43:99 (1971).Google Scholar
  27. 27.
    K.W.E. Denson, G.I.C. Ingram, Antigen/biologival-activity ratio for factor VIII. Lancet, 1: 1973.Google Scholar
  28. 28.
    K.W.E. Denson, In: Human blood coagulation, haemostasis and thrombosis. Ed. by: Biggs R., Blackwell Scientific Publications, Oxford-Edinburgh, 1976.Google Scholar
  29. 29.
    M. Ekberg, I.M. Nilsson, Factor VIII and glomerulonephritis. Lancet 1: 1111 (1975).PubMedCrossRefGoogle Scholar
  30. 30.
    A.P. Fletcher, N. Alkjaersig, O. Owens, G. Wolff, J.R. Smith, Blood hypercoagulability, thrombosis and acute myocardial infarction. J. Lab. Clin. Med. 78:798 (1971).PubMedGoogle Scholar
  31. 31.
    A.P. Fletcher, N. Alkjaersig, Blood screening methods for the diagnosis of venous thrombosis. Milkbank Mem. Fund. Q. 50: 170 (1972).CrossRefGoogle Scholar
  32. 32.
    A. Girolami, A. Sticchi, T. Barbui, G. Bareggi, Factor VIII immunological assay. An evaluation of several methods using whole plasma. Blut. Band XXIX:309 (1974).Google Scholar
  33. 33.
    H.L. Goldsmith, The flow of model particles and blood cells and its relation to thrombogenesis. In: Spet T.H. (ed.): Progress in haemostasis and thrombosis. Grune and Stratton, New York, 1972.Google Scholar
  34. 34.
    J. Gormsen, J.D. Nielsen, L.A. Andersen, ADP-induced platelet aggregation in patients with ischemic heart disease and peripheral thrombo-atherosclerosis. Acta Med. Scand. 201: 509 (1977).PubMedCrossRefGoogle Scholar
  35. 35.
    J.W. Haerem, Platelets and sudden death. In: Neri Serneri G.G., Mason, D.T. (eds.): Myocardial Infarction. Excerpta Medica, Amsterdam, p. 30, 1979.Google Scholar
  36. 36.
    M.D. Haust, R.H. Moore, Development of modern theories on tne pathogenesis of atherosclerosis, In: Wissler R.W., Geer J.C. (eds.): The pathogenesis of atherosclerosis, p. 1, Williams & Wilkins, Baltimora 1972.Google Scholar
  37. 37.
    E.J. Hershgold, A.M. Davison, M.E. Jansgen, Human F. VIII (antihemophilic factor): activation and inactivation by phospho-lipases. J. Lab. Clin. Med. 77:206 (1971).PubMedGoogle Scholar
  38. 38.
    E.J. Hershgold, A.M. Davison, M.E. Jansgen, Isolation and some clinical properties of human F. VIII J. Lab. Clin. Med. 77: 185 (1971).PubMedGoogle Scholar
  39. 39.
    H. Holmsen, Prostaglandin endoperoxide-thromboxane synthesis and dense granuli secretion as positive feedback loops in the propagation of platelet responses during “the basic platelet reaction”. Thromb. Haemost. 38:1030 (1977).PubMedGoogle Scholar
  40. 40.
    P.W. Howie, C.B. Begg, D.W. Purdie, & coll. Use of coagulation tests to predict the clinical progress of pre-eclampsia. Lancet 2:323 (1976).PubMedCrossRefGoogle Scholar
  41. 41.
    J. Hudson, W.T.E. McCaughy, Mural thrombosis and atherogenesis in coronary arteries and aorta. An investigation using anti-fibrin and antiplatelet sera. Atherosclerosis 19:543 (1974).PubMedCrossRefGoogle Scholar
  42. 42.
    A. Huges, R.S. Tonks, The role of microemboli in the production of carditis in hypersensitivity experiments. J. Path. Bacte-riol. 77:207 (1959).CrossRefGoogle Scholar
  43. 43.
    E.A. Jaffe, L.W. Hoyer, R.L. Nachman, Synthesis of antiemophilic factor antigen by cultured human endothelial cells. J. Clin. Invest. 52:2757 (1973).PubMedCrossRefGoogle Scholar
  44. 44.
    E.A. Jaffe, L.W. Hoyer, R.L. Nachman, Synthesis of von Willebrand factor by cultured human endothelial cells. Proc. Natl. Acad. Sci. USA, 7:190 (1974).Google Scholar
  45. 45.
    E.A. Jaffe, R.L. Nachman, Submit structure of factor VIII antigen synthetized by cultured human endothelial cells. J. Clin. Invest. 56:698 (1975).PubMedCrossRefGoogle Scholar
  46. 46.
    E.A. Jaffe, Endothelial cells and the biology of factor VIII. Nature 296:377 (1977).Google Scholar
  47. 47.
    C.L. Janssen, W.M. van Leuwen, Behaviour of factors V and factor VII during the process of blood coagulation. Scand. J. Haemat. 9:531 (1972).PubMedCrossRefGoogle Scholar
  48. 48.
    L. Jorgensen, T. Hovig, H.C. Roswell, J.F. Mustard, Adenosine diphosphate induced platelet aggregation and vascular injury in swine and rabbits. Am. J. Pathol. 61:161 (1970).PubMedGoogle Scholar
  49. 49.
    L. Jorgensen, M.A. Packham, H.C. Roswell, M.R. Buchanan, J.F. Mustard, Local aortic injury caused by cannulation: increased plasma protein accumulation and thrombosis. Acta Path. Microbiol.Scand. 82:637 (1974).Google Scholar
  50. 50.
    K.L. Kaplan, H.L. Nossel, M. Drillings, G. Lesznik, Radioim munoassay of platelet factor 4 and beta-thromboglobulin: development and application to studies of platelet release in relation to fibrinipeptide A generation. Br. J. Haematol. 38:129 (1978).CrossRefGoogle Scholar
  51. 51.
    M. Kazama, T. Abe, Change of the molecular mass of fibrinogen in circulating blood, as an index of hypercoagulable states. Thromb. Res. 8:(Suppl. II) 133 (1976).PubMedCrossRefGoogle Scholar
  52. 52.
    P.E.A. Kernoff, Affinity of factor VIII clotting activity for antigen detectable immunologically. Nature. New Biology 244:148 (1973).PubMedGoogle Scholar
  53. 53.
    B.A. Kottke, M.T.R. Subbiah, Subject review pathogenesis of atherosclerosis, concepts based on animal models. Mayo Clin. Proc. 53:35 (1978).PubMedGoogle Scholar
  54. 54.
    J.L. Lane, P. Bird, C.R. Rizza, A new assay for measurement of total progressive antithrombin. Br. J. Haematol. 30:103 (1975).PubMedCrossRefGoogle Scholar
  55. 55.
    C.B. Laurell, Quantitative estimation of proteins by elettro-phoresis in agarose gel containing antibodies. Analitical Biochemistry 15:45 (1966).CrossRefGoogle Scholar
  56. 56.
    C.B. Laurell, Electroimmuno assay. Scand. J. Clin. Lab. Invest. 29, suppl. 124:21 (1972).CrossRefGoogle Scholar
  57. 57.
    E.C. Lian, R.R. Minej, D.R. Harnnes, In vitro and in vivo effects of thrombin and plasmin on human factor VIII (AHF). Am. J. Haemat. 1:481 (1976).CrossRefGoogle Scholar
  58. 58.
    C.A. Ludlam, J.D. Cash, Studies on the liberation of betathromboglobulin from human platelets in vitro. Brit. J. Haematol. 33:239 (1976).CrossRefGoogle Scholar
  59. 59.
    C.A. Ludlam, Beta-thromboglobulin. A new diagnostic tool in the diagnosis of hypercoagulability? In: Neri Serneri G.G., Prentice C.R.M. (eds.): Florence Conference on Haemostasis and Thrombosis. Academic Press, London 1977.Google Scholar
  60. 60.
    P.M. Mannucci, F.I. Pareti, L. Holmberg, I.M. Nilsson, Z.M. Ruggeri, Studies on the prolonged bleeding time in von Willebrand’s disease. J. Lab. Clin. Med., October, 662 (1976).Google Scholar
  61. 61.
    E.E. Mayne, J.M. Bridges, J.A. Weawer, Platelet adhesiveness, plasma fibrinogen and factor VIII levels in diabetes mellitus. Diabetologia. 6:436 (1970).PubMedCrossRefGoogle Scholar
  62. 62.
    S. Moore, D.S. Pepper, J.D. Cash, The isolation and characterization of a platelet specific release beta-globulin: beta-thromboglobulin and the detection of antiurokinase and anti-plasmin released from thrombin aggregated washed human platelets. Bioch. Biophys. Acta 379:360 (1975).CrossRefGoogle Scholar
  63. 63.
    M. Moroi, N. Aoki, Inhibition of plasminogen binding to fibrin by alpha-2-plasmin inhibitor. Thromb. Res. 10:851 (1977a).PubMedCrossRefGoogle Scholar
  64. 64.
    M. Moroi, N. Aoki, On the interaction of alpha-2-plasmin inhibitor and proteases. Evidence for the formation of a covalent crosslinkage and non-covalent weak bindings between the inhibitor and proteases. Bioch. Biophys. Acta 482:412 (1977b).CrossRefGoogle Scholar
  65. 65.
    R.L. Nachman, E.A. Jaffe, Subcellular platelet factor VIII antigen and von Willebrand factor. J. Exp. Med. 141:1101 (1975).PubMedCrossRefGoogle Scholar
  66. 66.
    P. Needleman, P.S. Kulkarni, A. Raz, Coronary tone modulation: formation and actions of prostaglandins endoperoxides and thromboxanes. Science 195:409 (1977).PubMedCrossRefGoogle Scholar
  67. 67.
    G.G. Neri Serneri, G.F. Gensini, R. Abbate, D. Prisco, C. Mugnaini, Soluble fibrinogen complexes and platelet aggregates in patients with history of myocardial infarction and chronic cerebrovascular disorders. A rationale for prophylactic therapy. Europ. Symp. on Platelet Aggregation, Coagulation Fibrinolysis and Atherosclerosis. (A. Strano ed.) p. 277, CEPI, Roma, 1976.Google Scholar
  68. 68.
    G.G. Neri Serneri, R. Abbate, G.F. Gensini, G. Masotti, Aterosclerosi e stati trombofilici. In: Atti dell’Ottantesimo Congresso della Società Italiana di Medicina Interna, p. 427, Pozzi L., Roma, 1979.Google Scholar
  69. 69.
    G.G. Neri Serneri, Relationships between system and ischaemic heart disease. In: Neri Serneri G.G., Mason T.D. (eds.): Myocardial Infarction. Excerpta Medica, Amsterdam, 1979.Google Scholar
  70. 70.
    G.G. Neri Serneri, High molecular weight fibrinogen complexes in the assessment of hypercoagulability, In: Neri Serneri G.G., Prentice C.R.M. (eds.) Haemostasis and Thrombosis, p. 211. Academic Press, London 1979.Google Scholar
  71. 71.
    H.L. Nossel, I. Yudelman, R.E. Canfield, Measurement of fibrino-peptide A in human blood. J. Clin. Invest. 54:43 (1974).PubMedCrossRefGoogle Scholar
  72. 72.
    J.R. O’Brien, M.D. Etherington, S. Jamieson, P. Lawford, S.V. Lincoln, N.J. Alkjaersig, Blood changes in atherosclerosis and long after myocardial infarction and venous thrombosis. Thromb. Diath. Haemorrh. 34:483 (1975).PubMedGoogle Scholar
  73. 73.
    M. Pandolfi, L.O. Aimer, L. Holmberg, Increased von Willebrand antiemophylic factor in diabetic retinopathy. Acta Ophtalmol. 52:823 (1974).CrossRefGoogle Scholar
  74. 74.
    F. Panicucci, A. Sacripanti, E. Pinori, M. Vispi, B. Conte, L. Lecchini, Antithrombin III, heparin cofactor and anti-factor Xa in relation to age, sex and pathological conditions. Thromb. Haemost. 42:127 (1979).Google Scholar
  75. 75.
    S. Renaud, K. Kuba, C. Goulet, Y. Lemire, C. Allard, Relationship between fatty-acid composition of platelets and platelet aggregation in rat and man. Circ. Res. 26:343 (1970).CrossRefGoogle Scholar
  76. 76.
    R.D. Rosenberg, P.S. Damus, The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 248:6490 (1973).PubMedGoogle Scholar
  77. 77.
    J.S. Rosenberg P. McKenna, R.D. Rosenberg, Inhibition of human factor IX by human antithrombin-hepatin cofactor. J. Biol. Chem. 250:8883 (1975).PubMedGoogle Scholar
  78. 78.
    R.D. Rosenberg, G. Armand, L. Lam, Structure-function relationship of heparin species. Proc. Natl. Sci. USA 75:3065 (1978).CrossRefGoogle Scholar
  79. 79.
    R. Ross, J. Glomset, B. Kariya, R. Harker, A platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc. Natl. Sci. USA 71:1207 (1974).CrossRefGoogle Scholar
  80. 80.
    R. Ross, J. Glomset, The pathogenesis of atherosclerosis. New Engl. J. Med. 295:369 (1976).PubMedCrossRefGoogle Scholar
  81. 81.
    N. Salky, M. Dugdale, Platelet abnormalities in ischaemic heart disease. Am. J. Cardiol. 32:612 (1973).PubMedCrossRefGoogle Scholar
  82. 82.
    S.C. Sharma, H.N. Seth, Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in acute myocardial infarction Br. Heart J. 40:526 (1978).PubMedCrossRefGoogle Scholar
  83. 83.
    M.J. Silver, T.K. Bills, J.B. Smith, Platelets and prostaglandins: the key role of platelet phospholipase A2 activity. In: De Gaetano G., Garattini S. (eds.): Platelets: A multidisciplinary approach. Raven Press, New York, 1978.Google Scholar
  84. 84.
    J.B. Smith, C. Ingerirían, M.J. Silver, Persistence of thromboxane A-2 like material and platelet reíase inducing activity in plasma. J. Clin. Inv. 58:1119 (1976).CrossRefGoogle Scholar
  85. 85.
    J. Stibbe, Effect of exercise on F. VIII complex: proportional increase of Ristocetin cofactor (von Willebrand cofactor) and F. VIII AGN, but disproportional increase of F. VIII AHF. Thromb. Res., vol.10:163 (1977).PubMedCrossRefGoogle Scholar
  86. 86.
    H. Stormorken, J. Herikssen, S. Nitter-Hange, A. Hellem, Antithrombin III and arterial thromboembolism. In: A. Strano (ed.) Proceedings of European Symposium on Advances in Coagulation, Fibrinolysis, Platelet Aggregation and Atherosclerosis. p. 19, CE.P.I., Roma, 1978.Google Scholar
  87. 87.
    A. Strano, S. Novo, G. Davi, G. Avellone, A. Pinto, La sindrome trombofilica delle arteriopatie obliteranti degli arti in-feriori. In: Atti dell’Ottantesimo Congresso della Società Italiana di Medicina Interna, p. 535, Pozzi L. Roma, 1979.Google Scholar
  88. 88.
    A. Strano, S. Novo, Prospettive sull’impiego degli antiaggreganti piastrinici nellTarteriosclerosi. Editoriale Giorn. Ital. Cardiol. 9:1 (1979).Google Scholar
  89. 89.
    A. Strano, S. Novo, G. Davi, G. Avellone, Fisiopatologia della coagulazione, dell’aggregazione piastrinica nella cardio-patia ischemica. In: Atti del XXXVIII Congresso Nazionale della Società Italiana di Cardiología, suppl. Boll. Soc. Ital. Cardiol., p. 499, Roma, 1980.Google Scholar
  90. 90.
    T. Strasser, Atherosclerosis and coronary heart disease: the contribution of epidemiology. WHO Chron. 26:7 (1972).PubMedGoogle Scholar
  91. 91.
    J. Svensson, M. Hamberg, B. Samuelsson, Prostaglandin endo-peroxides IX. Characterization of rabbit aorta contracting substance (RCS) from guinea pig lung and human platelets. Acta Physiol. Scand. 94:222 (1975).PubMedCrossRefGoogle Scholar
  92. 92.
    M.E. Switzer, P.A. McKee, Some effects of calcium on the activation of human factor VIII: von Willebrand factor protein by thrombin. J. Clin. Invest. 60:819 (1977).PubMedCrossRefGoogle Scholar
  93. 93.
    A. Teien, V. Abildgaard, M. Höök, The anticoagulant effect of heparin sulphate and dermatan sulphate. Thromb. Res. 8: 859 (1976).PubMedCrossRefGoogle Scholar
  94. 94.
    Z.I. Terashita, H. Fukui, K. Nishikawa, M. Hirata, S. Kikuchi, Coronary vasospastic action of thromboxane A2 in isolated working guinea pig hearts. Europ. J. Pharmacol. 53:94 (1978).CrossRefGoogle Scholar
  95. 95.
    C. Thomson, C.D. Forbes, C.R.M. Prentice, Relationship of factor VIII to Ristocetin induced platelet aggregation: effect of heterologous and acquired factor VIII antibodies. Thromb. Res. 3:363 (1973).CrossRefGoogle Scholar
  96. 96.
    J.F. Toole, R. Janeway, K. Choi, R. Cordell, F. Johnston, H.S. Muller, Transient ischemic attacks due to atherosclerosis: a prospective study of 160 patients. Arch. Neurol. 32:5 (1975).PubMedCrossRefGoogle Scholar
  97. 97.
    V.T. Turitto, H.R. Baumgartner, Platelet interaction with sub-endothelium in a perfusion system: physical role of red blood cells. Microvasc. Res. 9:335 (1975).PubMedCrossRefGoogle Scholar
  98. 98.
    E. von Kaulla, K.N. von Kauila, Antithrombin III and disease. Am. J. Clin. Pathol. 48:69 (1967).Google Scholar
  99. 99.
    P.N. Walsh, Albumin density gradient and washing of platelets and the study of platelet coagulant activities. Br. J. Haemat. 22:205 (1972).CrossRefGoogle Scholar
  100. 100.
    P.N. Walsh, Platelet coagulant activities and haemostasis: a hypothesis. Blood 43:597 (1974).PubMedGoogle Scholar
  101. 101.
    H.J. Weiss, L.W. Hoyer, R.F. Rickles, A. Varma, J. Rogers, Quantitative assay of a plasma factor deficient in von Willebrand disease that is necessary for platelet aggregation: relationship to decrease F. VIII procoagulant activity and antigen content. J. Clin. Invest. 52:2708 (1973).PubMedCrossRefGoogle Scholar
  102. 102.
    R.W. Wissler, Overview of problems of atherosclerosis. In: Scheinberg P. (ed.): Cerebrovascular disease, p. 56, Raven Press, New York, 1976.Google Scholar
  103. 103.
    S. Wessler, E.T. Yin, On the antithrombotic action of heparin. Thromb. Diath. Haemorrh. 32:71 (1974).PubMedGoogle Scholar
  104. 104.
    J.C. White, Electron microscopic studies of platelet secretion. Prog. Haemostas. Thromb. 2:49 (1974).Google Scholar
  105. 105.
    L.D. Witte, K.L. Kaplan, H.L. Nossel, B.A. Lages, H.J. Weiss, S.G. De Witt, Studies of the release from human platelets of the growth factor for cultured human arterial smooth muscle cells. Circ. Res. 42:402 (1978).PubMedCrossRefGoogle Scholar
  106. 106.
    N. Woolf, K.C. Carstairs, Infiltration and thrombosis in atherogenes is. A study using immunofluoréscent technique. Am. J. Pathol. 51:373 (1967).PubMedGoogle Scholar
  107. 107.
    E.T. Yin, L.C. Guidice, S. Wessler, Inhibition of activated factor X-induced platelet aggregation: the role of heparin and the plasma inhibitor to activated factor X. J. Clin. Med. 81:298 (1973).Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • G. Avellone
    • 1
  • V. Mandalà
    • 1
  • S. Novo
    • 1
  • A. Pinto
    • 1
  • F. P. Riolo
    • 1
  • F. Cannioto
    • 1
  • G. Raneli
    • 1
  1. 1.Institute of Clinical Medicine and Medical TherapyUniversity of PalermoPalermoItaly

Personalised recommendations